Publications

Our scientific publications

Explore Our Scientific Validation and Expertise

Our research has been validated through peer-reviewed publications and presentations at leading scientific conferences, detailing the analytical performance and clinical utility of our liquid biopsy platform. This section provides direct access to the data, clinical outcomes, and scientific methodology that underpin the accuracy and reliability of all LIQOMICS ctDNA tests, serving as a transparent source for all clinical partners.

Entirely noninvasive outcome prediction in central nervous system lymphomas using circulating tumor DNA

Heger et al.

Blood 2024; 143(6): 522–534

In-depth cell-free DNA sequencing reveals genomic landscape of Hodgkin's lymphoma and facilitates ultrasensitive residual disease detection

Sobesky et al.

Med 2021; 2(10): 1171-1194

Circulating Tumor DNA Sequencing for Biologic Classification and Individualized Risk Stratification in Patients With Hodgkin Lymphoma

Heger et al.

Journal of Clinical Oncology 2024

Lymphovista HL - a Validated Assay for Genotyping and MRD Assessment in Hodgkin Lymphoma

Mattlener et al.

Blood 2024; 144 (Supplement 1): 4355

Serial monitoring of circulating tumor DNA with an ultrasensitive assay facilitates outcome prediction in RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA treated with modern agents

Schleifenbaum et al.

EHA library 05/14/24